Table 2.

Adjuvant radiotherapy in stage I–II endometrial cancer

Trial	Enrollment	No. of patients	Surgery	Eligibility	Randomization	Loco-regional recurrence	Survival
GOG-994	1987–1995	392	TH-BSO+LND	Stages IB/C; stage II (occult)	EBRT vs NAT	2 years: 3% vs 12% (p=0.007)	4 years: 86% vs 92% (p=0.0557)
PORTEC-15	1990–1997	714	TH-BSO	Stages IB G2-3; stages IC G1-2	EBRT vs NAT	5 years: 4% vs 14% (p<0.001)	5 years: 85% vs 81% (p=0.31)
Swedish7	1997–2008	527	TH-BSO	Stage I intermediate risk	VBT vs VBT+EBRT	5 years: 5% vs 1.5% (p=0.013)	5 years: 90% vs 89% (p=0.55)
ASTEC/EN.56	1996–2008	905	TH-BSO±LND	Stages IA/B G3; IC; stage II; serous/CC	EBRT vs NAT	5 years: 6% vs 3% (p=0.02)	5 years: 84% vs 84% (p=0.98)
PORTEC-28	2002–2006	427	TH-BSO	Age >60 and stage IB G3 or stages IC G1-2; stage IIA	EBRT vs VBT	5 years: 5% vs 2% (p=0.17)	5 years: 85% vs 80% (p=0.57)

LND; lymph node dissection G; grade; LND; lymph node G; grade; EBRT, external beam radiation therapy; GOG, Gynaecologic Oncology Group; NAT, no adjuvant treayment; PORTEC, Post Operative Radiation Therapy for Endometrial Carcinoma; TH-BSO, total hysterectomy and bilateral salpingo-oophorectomy; VBT, vaginal brachy therapy.